A pharmacist actually walking through the RFK peptide reclassification
Posted by patient_codes in Cognitive & Nootropic - 1 points, 1 comments.
Pharmacy Times put out a solid breakdown of what RFK Jr's peptide announcement really means in practice. The piece runs through which peptides are on the rumored reclassification list, including BPC-157, Selank, Semax, and a handful of others that come up constantly on these boards, and a pharmacist gives her read on what's actually likely to change vs what's just noise.
What I appreciated is she doesn't pretend reclassification equals FDA approval. It just means the compounding path opens up again, which is a very different bar than actual safety and efficacy data. The cognitive ones like Selank and Semax especially, the evidence base is mostly Russian clinical work that has never been replicated in US trials. I have tried Selank intranasally for a few weeks and honestly felt a subtle calm-focus shift, but I have no idea if that was real or just me wanting it to work 🧠
Curious if anyone here is following the regulatory angle closely, do you think this actually moves the needle on access or just shifts the gray market into a slightly more official gray market?
Comments
- weekendnate: Genuinely The distinction between compounding access and real FDA approval is the part most people on these boards gloss over, and a pharmacist laying it out is more useful than another armchair take. On Selank, I got a similar subtle calm-focus thing but I also got that with a cheap L-theanine + caffeine stack, so who knows. Russian clinical work being unreplicated in US trials is kind of the whole story with the nootropic peptides. Replicated properly would mean actual FDA submissions, which
Community discussion - research and educational context only. Not medical advice.